1. Signaling Pathways
  2. Cytoskeleton
  3. Myosin

Myosin

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Myosin Related Products (21):

Cat. No. Product Name Effect Purity
  • HY-13441
    (-)-Blebbistatin
    Inhibitor ≥98.0%
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
  • HY-15417
    ML-7 hydrochloride
    Inhibitor 99.75%
    ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits MLCK (IC50=300 nM). ML-7 hydrochloride also inhibits YAP/TAZ.
  • HY-109037
    Mavacamten
    Modulator ≥99.0%
    Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
  • HY-100685
    MS-444
    Inhibitor 99.13%
    MS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (MLCK) with an IC50 value of 10 μM.
  • HY-14233
    Omecamtiv mecarbil
    Activator 98.89%
    Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
  • HY-115669
    Pentachloropseudilin
    Inhibitor ≥98.0%
    Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β.
  • HY-139465
    Aficamten
    Inhibitor
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).
  • HY-141810
    MT-134
    Inhibitor
    MT-134 is a SkMII-specific inhibitor and has excellent exposure in muscles.
  • HY-13813
    Blebbistatin
    Inhibitor
    Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function.
  • HY-109128
    Danicamtiv
    Activator 99.49%
    Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
  • HY-100912
    W-7 hydrochloride
    Inhibitor 99.65%
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 µM, respectively. W-7 hydrochloride induces apoptosis and has antitumor activity.
  • HY-P1029
    MLCK inhibitor peptide 18
    Inhibitor 99.66%
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
  • HY-16690
    BTS
    Inhibitor ≥98.0%
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers.
  • HY-100984
    HA-100
    Inhibitor 99.77%
    HA-100 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 also used as a ROCK inhibitor.
  • HY-100932
    ML-9
    Inhibitor 99.89%
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
  • HY-100948B
    ATM-3507 trihydrochloride
    Inhibitor 98.10%
    ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
  • HY-120870
    para-Nitroblebbistatin
    Inhibitor
    para-Nitroblebbistatin is a non-cytotoxic, photostable, fluorescent and specific Myosin II inhibitor, usd in the study of the specific role of myosin II in physiological, developmental, and cell biological studies.
  • HY-100948
    ATM-3507
    Inhibitor
    ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.
  • HY-107657
    (+)-Blebbistatin
    Inhibitor
    (+)-Blebbistatin is the inactive enantiomer of (–)-Blebbistatin. (–)-Blebbistatin is a selective inhibitor of myosin II ATPase.
  • HY-100932A
    ML-9 Free Base
    Inhibitor
    ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.